{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:19:48Z","timestamp":1787995188538,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and immune checkpoint inhibitors (ICI) in patients with stage IVB cervical cancer (CC) based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 38 patients with stage IVB CC, as classified by the 2018 FIGO cervical cancer staging system, who received pelvic external beam radiotherapy (\u2265\u200940\u00a0Gy) with or without brachytherapy and chemotherapy. Data were collected from two centers. The 2-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were analyzed using the Kaplan\u2013Meier method. Symptom relief, including reductions in genital bleeding and pain from the primary lesion, was assessed. Acute and late adverse events were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up period was 17.5 months. The 2-year LC, PFS, and OS were 82%, 11%, and 47%, respectively. Although the evaluation method has limitations, most patients with genital bleeding and pain from the primary lesion showed improvement in symptoms. Late adverse events of grade\u2009\u2265\u20092 related to both pelvic radiotherapy and bevacizumab included one case of grade 3 gastrointestinal bleeding and two cases of grade 2 fistula.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This two-center study demonstrated that high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and ICI, may achieve favorable local control and symptom relief in patients with stage IVB CC while maintaining an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-025-01923-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:32:14Z","timestamp":1766550734000},"page":"719-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9952-0863","authenticated-orcid":false,"given":"Takaaki","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamasa","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonobu","family":"Kunitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1923_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/AOG.0000000000003311","volume":"134","author":"JD Wright","year":"2019","unstructured":"Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines. Obstet Gynecol. 2019;134:49\u201357.","journal-title":"Obstet Gynecol"},{"key":"1923_CR2","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, et al. First-Line Pembrolizumab\u2009+\u2009Chemotherapy versus Placebo\u2009+\u2009Chemotherapy for Persistent, Recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41:5505\u201311.","journal-title":"J Clin Oncol"},{"key":"1923_CR3","unstructured":"National Comprehensive Cancer Network (NCCN). Cervical cancer (version 3.2024). National Comprehensive Cancer Network; Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf [Accessed 24 Sep 2024]."},{"key":"1923_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","volume":"33","author":"D Cibula","year":"2023","unstructured":"Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, et al. ESGO \/ESTRO\/ ESP guidelines for the management of patients with cervical cancer \u2013 Update 2023*. Int J Gynecol Cancer. 2023;33:649\u201366.","journal-title":"Int J Gynecol Cancer"},{"key":"1923_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaoncol.2018.2677","volume":"4","author":"Y Wang","year":"2018","unstructured":"Wang Y, Farmer M, Izaguirre EW, Schwartz DL, Somer B, et al. Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer. JAMA Oncol. 2018;4:1288\u201391.","journal-title":"JAMA Oncol"},{"key":"1923_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3390\/curroncol28030155","volume":"28","author":"S Hattori","year":"2021","unstructured":"Hattori S, Yoshikawa N, Mogi K, Yoshida K, Yoshihara M, et al. Significance of concurrent chemoradiotherapy as primary treatment in patients with metastatic cervical cancer. Curr Oncol. 2021;28:1663\u201372.","journal-title":"Curr Oncol"},{"key":"1923_CR7","doi-asserted-by":"crossref","unstructured":"Mukai Y, Koike I, Matsunaga T, Yokota NR, Takano S et al. Radiation Therapy for Uterine Cervical Cancer With Lung Metastases Including Oligometastases. In vivo. 2019; 33: 1677-84.","DOI":"10.21873\/invivo.11655"},{"key":"1923_CR8","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Teweri","year":"2017","unstructured":"Teweri KS, Sill MW, Penson RT, Huang H, Ramondetta LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240). Lancet. 2017;390:1654\u201363.","journal-title":"Lancet"},{"key":"1923_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/ GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1321\u201332.","journal-title":"Lancet"},{"key":"1923_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ygyno.2015.09.079","volume":"139","author":"YJ Kim","year":"2015","unstructured":"Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, et al. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015;139:553\u201358.","journal-title":"Gynecol Oncol"},{"key":"1923_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jrr\/rrw109","volume":"58","author":"T Ohno","year":"2017","unstructured":"Ohno T, Wakatsuki M, Toita T, Kaneyasu Y, Yoshida K, et al. Recommendations for high risk clinical target volume definition with computed tomography for three-dimensional image guided brachytherapy in cervical cancer patients. J Radiat Res. 2017;58:341\u201350.","journal-title":"J Radiat Res"},{"key":"1923_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","volume":"74","author":"C Haie-Meder","year":"2005","unstructured":"Haie-Meder C, P\u00f6tter R, Limbergen EV, Briot E, Brabandere MD, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working Group* (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235\u201345.","journal-title":"Radiother Oncol"},{"key":"1923_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1923_CR14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","volume":"82","author":"E Chow","year":"2012","unstructured":"Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82:1730\u201337.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1923_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijrobp.2023.07.046","volume":"118","author":"A Laville","year":"2024","unstructured":"Laville A, Ka K, El-Ayachi R, Achkar S, Bockel S, et al. Locoregional treatment in patients with metastatic cervical cancer: benefit of dose escalation strategies. Int J Radiat Oncol Biol Phys. 2024;118:192\u2013202.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1923_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","volume":"22","author":"R P\u00f6tter","year":"2021","unstructured":"P\u00f6tter R, Tanderup K, Schmid MP, J\u00fcrgenliemk-Schulz I, Haie-Meder C, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22:538\u201347.","journal-title":"Lancet Oncol"},{"key":"1923_CR17","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.22.01096","volume":"41","author":"MP Schmid","year":"2023","unstructured":"Schmid MP, Lindegaard JC, Mahantshetty U, Tanderup K, Jurgenliemk-Schulz I, et al. Risk factors for local failure following chemoradiation and magnetic resonance image\u2013guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. J Clin Oncol. 2023;41:1933\u201342.","journal-title":"J Clin Oncol"},{"key":"1923_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ygyno.2020.03.006","volume":"157","author":"F Mignot","year":"2020","unstructured":"Mignot F, Gouy S, Schernberg A, Bockel S, Espenel S, et al. Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy. Gynecol Oncol. 2020;157:644\u20138.","journal-title":"Gynecol Oncol"},{"key":"1923_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, et al. Paclitaxel plus carboplatin versus Paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33:2129\u201335.","journal-title":"J Clin Oncol"},{"key":"1923_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-019-1297-x","volume":"14","author":"Z Yin","year":"2019","unstructured":"Yin Z, Lou H, Tang H, Ni J, Zhou Q, et al. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer. Radiat Oncol. 2019;14:82.","journal-title":"Radiat Oncol"},{"key":"1923_CR21","doi-asserted-by":"publisher","first-page":"100963","DOI":"10.1016\/j.gore.2022.100963","volume":"40","author":"RL Wiley","year":"2022","unstructured":"Wiley RL, Bondre IL, Jalloul R, Klopp AH, Taylor JS, et al. Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab \u2013 an exploratory study. Gynecol Oncol Rep. 2022;40:100963.","journal-title":"Gynecol Oncol Rep"},{"key":"1923_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ygyno.2022.03.022","volume":"165","author":"G Salvo","year":"2022","unstructured":"Salvo G, Jhingran A, Ramalingam P, Legarreta AF, Bhosale P, et al. Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: a nectur study. Gynecol Oncol. 2022;165:530\u20137.","journal-title":"Gynecol Oncol"},{"key":"1923_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.radonc.2011.01.009","volume":"98","author":"L van Lonkhuijzen","year":"2011","unstructured":"van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol. 2011;98:287\u201391.","journal-title":"Radiother Oncol"},{"key":"1923_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/ GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403:1341\u201350.","journal-title":"Lancet"},{"key":"1923_CR25","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","volume":"22","author":"DH Moore","year":"2004","unstructured":"Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, et al. Phase III study of cisplatin with or without Paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113\u201319.","journal-title":"J Clin Oncol"},{"key":"1923_CR26","first-page":"511","volume":"37","author":"K Chikazawa","year":"2016","unstructured":"Chikazawa K, Netsu S, Konno R. Outcomes of concurrent radiotherapy and weekly paclitaxel\/carboplatin therapy in cervical cancer: a retrospective study. Eur J Gynecol Oncol. 2016;37:511\u201316.","journal-title":"Eur J Gynecol Oncol"},{"key":"1923_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12885-024-12358-8","volume":"24","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jiang P, Chen Z, Li W, Dong B, et al. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer. BMC Cancer. 2024;24:589.","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01923-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:35:24Z","timestamp":1774935324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01923-1","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committees of the National Hospital Organization Kyushu Cancer Center (approval number: 2024-06) and Kyushu University Hospital (approval number: 241378). The requirement for informed consent was waived due to the study\u2019s retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}